Overview of the Acquisition#
India’s Sun Pharmaceutical Industries has announced its agreement to acquire U.S.-listed Organon & Co in a significant all-cash deal valued at approximately $11.75 billion. This acquisition aims to bolster Sun Pharma's global presence and expand its offerings in branded generics, innovative medicines, and biosimilars, which are biologic medical products highly similar to already approved reference products.
Details of the Deal#
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash. This move is part of Sun Pharma's strategy to enhance its portfolio, particularly in women’s health, where Organon has a strong focus. The acquisition will provide Sun Pharma access to Organon’s extensive portfolio of over 70 products, which includes various medications for women's health and general medical needs. Additionally, Organon operates in more than 140 markets worldwide.
Financial Insights#
Organon, which was spun off from Merck in 2021, reported a revenue of $6.2 billion and an adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $1.9 billion for the year 2025. Following the acquisition, Sun Pharma anticipates that the combined company will generate pro forma revenue of around $12.4 billion, positioning it among the top 25 global pharmaceutical firms.
Future Outlook#
The acquisition has been approved by the boards of both companies and is expected to close in early 2027, pending regulatory and shareholder approvals. Sun Pharma plans to finance this transaction through a combination of cash and committed bank financing, aiming to solidify its position as a leading player in the global pharmaceutical landscape, particularly in women’s health and biosimilars.